PLoS ONE (Jan 2014)

Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus.

  • Babs E Verstrepen,
  • Herman Oostermeijer,
  • Zahra Fagrouch,
  • Melanie van Heteren,
  • Henk Niphuis,
  • Tom Haaksma,
  • Ivanela Kondova,
  • Willy M Bogers,
  • Marina de Filette,
  • Niek Sanders,
  • Linda Stertman,
  • Sofia Magnusson,
  • Orsolya Lőrincz,
  • Julianna Lisziewicz,
  • Luisa Barzon,
  • Giorgio Palù,
  • Michael S Diamond,
  • Stefan Chabierski,
  • Sebastian Ulbert,
  • Ernst J Verschoor

DOI
https://doi.org/10.1371/journal.pone.0112568
Journal volume & issue
Vol. 9, no. 11
p. e112568

Abstract

Read online

The mosquito-borne West Nile virus (WNV) causes human and animal disease with outbreaks in several parts of the world including North America, the Mediterranean countries, Central and East Europe, the Middle East, and Africa. Particularly in elderly people and individuals with an impaired immune system, infection with WNV can progress into a serious neuroinvasive disease. Currently, no treatment or vaccine is available to protect humans against infection or disease. The goal of this study was to develop a WNV-vaccine that is safe to use in these high-risk human target populations. We performed a vaccine efficacy study in non-human primates using the contemporary, pathogenic European WNV genotype 1a challenge strain, WNV-Ita09. Two vaccine strategies were evaluated in rhesus macaques (Macaca mulatta) using recombinant soluble WNV envelope (E) ectodomain adjuvanted with Matrix-M, either with or without DNA priming. The DNA priming immunization was performed with WNV-DermaVir nanoparticles. Both vaccination strategies successfully induced humoral and cellular immune responses that completely protected the macaques against the development of viremia. In addition, the vaccine was well tolerated by all animals. Overall, The WNV E protein adjuvanted with Matrix-M is a promising vaccine candidate for a non-infectious WNV vaccine for use in humans, including at-risk populations.